New transplant combo aims to boost survival in blood cancer patients
NCT ID NCT07214688
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 41 times
Summary
This phase 2 trial is testing a new combination of chemotherapy, radiation, and immune-suppressing drugs for people aged 18-65 with blood cancers who need a stem cell transplant. The goal is to see if this regimen improves survival one year after the transplant. About 209 participants will receive the treatment at multiple centers.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALLOGENEIC STEM CELL TRANSPLANT RECIPIENT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
John Theurer Cancer Center at Hackensack University Medical Center
RECRUITINGHackensack, New Jersey, 07601, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
John Theurer Cancer Center at Jersey Shore University Medical Center
NOT_YET_RECRUITINGNeptune City, New Jersey, 07753, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Lombardi Comprehensive Cancer Center at Georgetown University Medical Center
NOT_YET_RECRUITINGWashington D.C., District of Columbia, 20007, United States
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
fludarabine, total body irradiation, cyclophosphamide, tacrolimus
What this could lead to
If successful, this could offer a safer and more effective stem cell transplant regimen for people with blood cancers, potentially improving survival rates.
What could go wrong
This is a phase 2 trial, so it is still early. The regimen may not improve survival and could cause serious side effects like infection or graft-versus-host disease.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.